Drug Resistance to HIV-1 Integrase Inhibitors Among Treatment-Naive Patients in Beijing, China

References

• Sterne JAC, Hernán MA, Ledergerber B, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet. 2005;366(9483):378–384.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Zhang M, Shi CX, et al. Mortality and virological failure among HIV-infected people who inject drugs on antiretroviral treatment in China: an observational cohort study. Drug Alcohol Depend. 2017;170:189–197.
   PubMed Web of Science ®Google Scholar
• Godfrey C, Bobkova M, Boucher C, et al. Regional challenges in the prevention of human immunodeficiency virus drug resistance. J Infect Dis. 2017;216(suppl_9):S816–S819.
   PubMed Web of Science ®Google Scholar
• World Health Organization. HIV Drug Resistance Report 2017. Geneva: World Health Organization; 2017.
   Google Scholar
• World Health Organization. HIV Drug Resistance Report 2019. Geneva: World Health Organization; 2019.
   Google Scholar
• Wittkop L, Günthard HF, de Wolf F, et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis. 2011;11(5):363–371.
   PubMed Web of Science ®Google Scholar
• AIDS and Hepatitis C Professional Group SoID, Chinese Medical Association, Chinese Center for Disease Control and Prevention. Chinese guidelines for diag-nosis and treatment of HIV/AIDS (version 2018). Chin J Intern Med. 2018;57:867–884.
   PubMedGoogle Scholar
• Blanco J, Whitlock G, Milinkovic A, Moyle G. HIV integrase inhibitors: a new era in the treatment of HIV. Expert Opin Pharmacother. 2015;16:1313–1324.
   PubMed Web of Science ®Google Scholar
• Mbhele N, Chimukangara B, Gordon M. HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance. Int J Antimicrob Agents. 2021;57(5):106343.
   PubMed Web of Science ®Google Scholar
• Gallant J, Lazzarin A, Mills A, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, Abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, Phase 3, randomised controlled non-inferiority trial. The Lancet. 2017;390(10107):2063–2072.
   PubMed Web of Science ®Google Scholar
• Acosta RK, Willkom M, Martin R, et al. Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 Weeks. Antimicrob Agents Chemother. 2019;63:5.
   Web of Science ®Google Scholar
• Casadella M, van Ham PM, Noguera-Julian M, et al. Primary resistance to integrase strand-transfer inhibitors in Europe. J Antimicrob Chemother. 2015;70(10):2885–2888.
   PubMed Web of Science ®Google Scholar
• Ji H, Patterson A, Taylor T, et al. Prevalence of Primary Drug Resistance Against HIV-1 Integrase Inhibitors in Canada. J Acquir Immune Defic Syndr. 2018;78(1):e1–e3.
   PubMed Web of Science ®Google Scholar
• Stekler JD, McKernan J, Milne R, et al. Lack of resistance to integrase inhibitors among antiretroviral-naive subjects with primary HIV-1 infection, 2007-2013. Antivir Ther. 2015;20(1):77–80.
   PubMed Web of Science ®Google Scholar
• Deng XM, Liu JF, Zhang M. Mutations of primary integrase gene resistance of HIV/AIDS patients in Yunnan province. Clin J AIDS STD. 2019;25(4):327–341.
   Google Scholar
• Yin YQ, Lu J, Zhou Y, et al. Drug Resistance to HIV-1 Integrase Inhibitors among Treatment-naive Patients in Jiangsu, China. Biomed Environ Sci. 2021;34(5):400–403.
   PubMed Web of Science ®Google Scholar
• Lan Y, Li L, Chen W, et al. Absence of Integrase Inhibitor-Associated Resistance Among Antiretroviral Therapy-Naive HIV-1-Infected Adults in Guangdong Province, China, in 2018. Infect Drug Resist. 2020;13:4389–4394.
   PubMed Web of Science ®Google Scholar
• Yan L, Yu F, Zhang H, et al. Transmitted and Acquired HIV-1 Drug Resistance from a Family: a Case Study. Infect Drug Resist. 2020;13:3763–3770.
   PubMed Web of Science ®Google Scholar
• Li M, Liang S, Zhou C, et al. HIV Drug Resistance Mutations Detection by Next-Generation Sequencing during Antiretroviral Therapy Interruption in China. Pathogens. 2021;10:264.
   PubMed Web of Science ®Google Scholar
• Liu L, Dai L, Yao J, et al. Lack of HIV-1 integrase inhibitor resistance among 392 antiretroviral-naïve individuals in a tertiary care hospital in Beijing, China. AIDS. 2019;33:1945–1947.
   PubMed Web of Science ®Google Scholar
• Standard University HIV Drug Resistance Database. HIVdb Program. Available from: https://hivdb.stanford.edu/hivdb/by-mutations/.
   Google Scholar
• Zhang F, Maria A, Haberer J, Zhao Y. Overview of HIV drug resistance and its implications for China. Chin Med J. 2007;119:1999–2004.
   Web of Science ®Google Scholar
• Zhao S, Feng Y, Hu J, et al. Prevalence of Transmitted HIV drug resistance in antiretroviral treatment naive newly diagnosed individuals in China. Sci Rep. 2018;8(1):12273.
   PubMedGoogle Scholar
• Liao L, Qing Y, Shang H, et al. The Prevalence of Transmitted Antiretroviral Drug Resistance in Treatment-Naive HIV-Infected Individuals in China. J Acquir Immune Defic Syndr. 2010;53(Suppl 1):S10–14.
   PubMed Web of Science ®Google Scholar
• Sluis-Cremer N. The emerging profile of cross-resistance among the nonnucleoside HIV-1 reverse transcriptase inhibitors. Viruses. 2014;6(8):2960–2973.
   PubMed Web of Science ®Google Scholar
• Adams J, Patel N, Mankaryous N, Tadros M, Miller CD. Nonnucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agents. Ann Pharmacother. 2010;44(1):157–165.
   PubMed Web of Science ®Google Scholar
• Fogel JM, Bonsall D, Cummings V, et al. Performance of a high-throughput next-generation sequencing method for analysis of HIV drug resistance and viral load. J Antimicrob Chemother. 2020;75(12):3510–3516.
   PubMed Web of Science ®Google Scholar
• Simen BB, Simons JF, Hullsiek KH, et al. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J Infect Dis. 2009;199(5):693–701.
   PubMed Web of Science ®Google Scholar
• Johnson J, Li J-F, Wei X, et al. Minority HIV-1 Drug Resistance Mutations Are Present in Antiretroviral Treatment–Naïve Populations and Associate with Reduced Treatment Efficacy. PLoS Med. 2008;5:e158.
   PubMed Web of Science ®Google Scholar